A Phase IV Study to Collect Data on the Efficacy and Safety of RIBociclib in Older Women With Breastcancer
- Conditions
- Breast Cancer
- Registration Number
- NCT03956654
- Lead Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Brief Summary
The RibOB study is a prospective, open lable, single arm trial which will evaluate the clinical efficacy, overall safety and tolerability of ribociclib in combination with letrozole in older women (≥70 years) with HR+/HER2- aBC and no prior hormonal treatment for advanced disease (as per approved indication).
- Detailed Description
The RibOB study is an observational prospective, open lable single arm phase IV trial which will evaluate the clinical efficacy, overall safety and tolerability of ribociclib in combination with letrozole in older women (≥70 years) with HR+, HER2- advanced breast cancer and no prior hormonal treatment for advanced disease as per the indication approved by the European Medicines Authority (EMA) and as made available by Belgian national authorities in the national health care system. A total of maximum 150 patients will be enrolled for treatment with Letrozole (2.5 mg once daily) + ribociclib 600 mg (day 1 to 21 in a 28 day cycle), which will continue until disease progression, intolerable toxicity or patient/physician decision to withdraw. During the study, patients will be continuously evaluated for disease progression as per national standard of care (approximately every 12 weeks radiologically); for safety; and for quality of life and geriatric assessment components including functional status with QoL assessment and CGA at 3 months (+/- 2 weeks) and at 1 year (+/-2 weeks).
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 78
- Patient is a female ≥ 70 years old at the time of informed consent.
- Advanced breast cancer (defined as locoregionally recurrent or metastatic not amenable to curative therapy).
- Histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive and/or progesterone receptor positive breast cancer by local laboratory (defined as ER and/or PgR ≥1% or Allred >2).
- HER2-negative breast cancer defined as a negative in situ hybridization test or an IHC status of 0, 1+ or 2+. If IHC is 2+, a negative in situ hybridization (FISH, CISH, or SISH) test as determined by local laboratory testing according to ASCO-CAP guidelines is necessary.
- Patient has adequate bone marrow and organ function as defined by the following laboratory values (as assessed by local laboratory), preferably tested a maximum of 14 days before enrolment:
- Patient has signed informed consent obtained before any trial-related activities and according to local guidelines.
- Subjects must be able to communicate with the investigator and comply with the requirements of the study procedures.
- Patient has a known hypersensitivity to any of the excipients of ribociclib or letrozole.
- Patients who received any CDK4/6 inhibitor previously.
- Patient who received any prior systemic antihormonal therapy or chemotherapy for advanced breast cancer.
- Patient is concurrently using other systemic anti-cancer therapy (except bone modifying agents).
- Patient with central nervous system (CNS) metastases and/or documented meningeal carcinomatosis unless they meet ALL the following criteria:
- At least 4 weeks from prior therapy for CNS disease completion (including radiation and/or surgery) to starting the study treatment;
- Clinically stable CNS lesions at the time of study treatment initiation and not receiving steroids and/or enzyme-inducing anti-epileptic medications for the management of brain metastases for at least 2 weeks (radiological confirmation of brain disease status is not necessary).
- Patient has any other concurrent severe and/or uncontrolled medical condition that would, in the investigator's judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical study or compromise compliance with the protocol: (e.g. chronic pancreatitis, chronic active hepatitis, active untreated or uncontrolled fungal, bacterial or viral infections, etc.).
- Patients who already have or who are at significant risk of developing QTc prolongation are not eligible for the study. This includes patients:
- with long QT syndrome;
- with uncontrolled or significant cardiac disease, including recent myocardial infarction, congestive heart failure, unstable angina and bradyarrhythmias;
- with electrolyte abnormalities (potassium, magnesium, sodium and calcium) that are NCI CTCAE 4.03 grade 2 or higher (for details, see table 10 ). Note: phosphate testing is not mandatory, but should the investigator consider measuring it before enrolment, the same rules may be applied
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression-free survival (PFS) 2018-2022 Clinical efficacy: Progression-free survival (PFS) (defined as the length of time from the start of treatment and death or progression of disease) as determined by the local investigator using RECIST 1.1 rules.
- Secondary Outcome Measures
Name Time Method Quality of Life (2) 2018-2022 Correlation of baseline QoL with OS
Comprehensive Geriatric Assessment 2018-2022 Evolution of CGA during study treatment
Plasma Biomarker Research (3) 2018-2022 Develop a plasma microRNA signature for response to study treatment (pre-dose cycle 3)
Plasma Biomarker Research (1) 2018-2022 Evolution of potential aging biomarkers during study treatment, and predictive value of baseline aging biomarkers on toxicity, PFS and OS (correcting for the prognostic metastatic index in PFS / OS)
Plasma Biomarker Research (2) 2018-2022 Predictive capacity of thymidine kinase on toxicity, PFS, OS and RR (correcting for the prognostic metastatic index in PFS, OS and RR). Thymidine kinase d1 versus d15 drop, and Thymidine kinase d15 level
Breast cancer specific survival (BCSS) 2018-2022 Efficacy: Breast cancer specific survival (BCSS). It is defined as the length of time from the start of treatment and death from breast cancer.
Treatment discontinuation 2018-2022 Safety: Number of patients who stop ribociclib before progression
Treatment interruption 2018-2022 Safety: number of patients needing dose interruption
PFS / OS 2018-2022 Prediction Modeling I: PFS and OS prognostic model based on clinical/pathologic characteristics
CGA / QoL 2018-2022 Prediction Modeling II: Baseline CGA and QoL and relation with PFS/OS
Quality of Life (1) 2018-2022 Evolution of QoL during study treatment: EORTC QLQ-C30 (modified) and EORTC IL15 questionnaires
Quality of Life (3) 2018-2022 Correlation of baseline QoL with toxicity grade III-IV
Overall response rate (ORR) 2018-2022 Efficacy: Overall response rate (ORR), for patients with measurable disease as determined locally by investigator according to RECIST 1.1. It is defined as the proportion of patients with best overall response of complete response (CR) or partial response (PR) according to RECIST 1.1.
Overall Survival (OS) 2018-2022 Efficacy: Overall survival (OS). It is defined as the length of time from the start of treatment and death from any cause.
Time to treatment failure (TTF) 2018-2022 Efficacy: Time to treatment failure (TTF). It is defined as time from date of start of treatment to the date of event defined as the first documented progression, death due to any cause or withdrawal from treatment.
Adverse events 2018-2022 Safety: Incidence of Adverse Events according to the NCI-CTCAE 4.03 during study treatment and according to the results of baseline CGA evaluation; Number of patients who stop ribociclib before progression ; number of patients needing dose interruption/reduction.
Treatment reduction 2018-2022 Safety: number of patients needing dose reduction
Plasma Biomarker Research (4) 2018-2022 Evaluation of plasma antitumor immunity induction by study treatment at day 15 of cycle 1.
Trial Locations
- Locations (1)
UZ Gasthuisberg Leuven
🇧🇪Leuven, Belgium